Tags : ICM

Biosimilars Insights+

Insights+ Key Biosimilars Events of March 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Hence, the providers are more likely to adopt biosimilars as a “reference product to biologics” possessing similar therapeutic properties The US FDA took an initiative to develop new pathways for Insulin biosimilars. Our team at PharmaShots has […]Read More


Biocad with its Partner ICM Received the Registration Certificate for

The partner received Registration Certificate for its Acellbia (biosimilar, rituximab) and Herticad (biosimilars, trastuzumab) in Bosnia and Herzegovina, countries on the Balkan Peninsula in Southeastern EU. The Agency for Medicinal Products and Medical Devices of Bosnia and Herzegovina has granted certificate with expected market launch in this year Biocad will be responsible to produce agents […]Read More